NASDAQ:CRBU - Caribou Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $29.67
  • Forecasted Upside: 22.19 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$24.28
▲ +0.25 (1.04%)

This chart shows the closing price for CRBU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Caribou Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRBU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRBU

Analyst Price Target is $29.67
▲ +22.19% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Caribou Biosciences in the last 3 months. The average price target is $29.67, with a high forecast of $32.00 and a low forecast of $27.00. The average price target represents a 22.19% upside from the last price of $24.28.

This chart shows the closing price for CRBU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Caribou Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/17/2021SVB LeerinkInitiated CoverageOutperform$32.00High
8/17/2021Bank of AmericaInitiated CoverageBuy$30.00High
8/17/2021CitigroupInitiated CoverageNeutral$27.00High
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021

Current Sentiment

  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Caribou Biosciences logo
Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in BERKELEY, Calif.
Read More

Today's Range

Now: $24.28
Low: $22.90
High: $24.39

50 Day Range

MA: $24.78
Low: $15.75
High: $30.29

52 Week Range

Now: $24.28
Low: $15.00
High: $32.65

Volume

8,117 shs

Average Volume

933,741 shs

Market Capitalization

$1.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Caribou Biosciences?

The following sell-side analysts have issued research reports on Caribou Biosciences in the last twelve months: Bank of America Co., Citigroup Inc., and SVB Leerink LLC.
View the latest analyst ratings for CRBU.

What is the current price target for Caribou Biosciences?

3 Wall Street analysts have set twelve-month price targets for Caribou Biosciences in the last year. Their average twelve-month price target is $29.67, suggesting a possible upside of 22.2%. SVB Leerink LLC has the highest price target set, predicting CRBU will reach $32.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $27.00 for Caribou Biosciences in the next year.
View the latest price targets for CRBU.

What is the current consensus analyst rating for Caribou Biosciences?

Caribou Biosciences currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRBU will outperform the market and that investors should add to their positions of Caribou Biosciences.
View the latest ratings for CRBU.

How do I contact Caribou Biosciences' investor relations team?

The company's listed phone number is 510-982-6030. The official website for Caribou Biosciences is cariboubio.com.